Nkarta, Inc. (NKTX) Stock Profile — Insider Trades & Financials

Net Income-$27.4M

EPS$-1.04

Market Cap$164.7M

Price Performance

Historical data including institutional events

Loading price data...

Company Profile

Paul Hastings

CEO & Executive Director

Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. Its lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen, which is in Phase 1 clinical trial for the treatment of lupus nephritis; systemic sclerosis; idiopathic inflammatory myopathy; and antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, as well as for systemic lupus erythematosus and myasthenia gravis. The company has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.

Founded: 2015
Employees: 108
Headquarters: South San Francisco, California, United States

⚡

Core Efficiency

ROE?

-8.78%

ROA?

-6.78%

D/E Ratio?

0.29

📊

Profitability Ratios

Current Ratio?

12.69

Loading comparison...

Earnings Calendar

Filing history and next expected filing date

Next Expected Filing

Aug 17, 2026 (in 130 days)

Annual Report (10-K) — Based on filing pattern

Aug 17, 2026

Predicted10-K

Mar 25, 2026

10-KQ4 20257d after period end

Nov 10, 2025

10-QQ3 20255d after period end

Aug 12, 2025

10-QQ2 20254d after period end

May 14, 2025

10-QQ1 20255d after period end

Mar 26, 2025

10-KQ4 20245d after period end

Nov 7, 2024

10-QQ3 20243d after period end

Aug 13, 2024

10-QQ2 20244d after period end

May 9, 2024

10-QQ1 20243d after period end

Loading company sections...

Nkarta, Inc.

Price Performance

Company Profile

Core Efficiency

Profitability Ratios

Earnings Calendar

Core Efficiency

Profitability Ratios

Earnings Calendar

Data Freshness